CN115463176A - 一种降血糖组合物、制备方法及其应用 - Google Patents
一种降血糖组合物、制备方法及其应用 Download PDFInfo
- Publication number
- CN115463176A CN115463176A CN202211143554.8A CN202211143554A CN115463176A CN 115463176 A CN115463176 A CN 115463176A CN 202211143554 A CN202211143554 A CN 202211143554A CN 115463176 A CN115463176 A CN 115463176A
- Authority
- CN
- China
- Prior art keywords
- hypoglycemic
- lactobacillus
- hypoglycemic composition
- parts
- blood sugar
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 76
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- 210000004369 blood Anatomy 0.000 title claims description 46
- 239000008280 blood Substances 0.000 title claims description 46
- 230000001603 reducing effect Effects 0.000 title claims description 27
- 230000002218 hypoglycaemic effect Effects 0.000 claims abstract description 65
- 239000006041 probiotic Substances 0.000 claims abstract description 42
- 235000018291 probiotics Nutrition 0.000 claims abstract description 42
- 244000144730 Amygdalus persica Species 0.000 claims abstract description 34
- 235000006040 Prunus persica var persica Nutrition 0.000 claims abstract description 34
- 239000002994 raw material Substances 0.000 claims abstract description 34
- 239000000463 material Substances 0.000 claims abstract description 33
- 240000006740 Cichorium endivia Species 0.000 claims abstract description 20
- 235000009811 Momordica charantia Nutrition 0.000 claims abstract description 20
- 235000003733 chicria Nutrition 0.000 claims abstract description 20
- 241000186604 Lactobacillus reuteri Species 0.000 claims abstract description 19
- 229940001882 lactobacillus reuteri Drugs 0.000 claims abstract description 19
- 244000234609 Portulaca oleracea Species 0.000 claims abstract description 18
- 235000001855 Portulaca oleracea Nutrition 0.000 claims abstract description 18
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims abstract description 17
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims abstract description 16
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims abstract description 16
- 229940009289 bifidobacterium lactis Drugs 0.000 claims abstract description 16
- 239000000843 powder Substances 0.000 claims abstract description 16
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 15
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 15
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 15
- 241000186605 Lactobacillus paracasei Species 0.000 claims abstract description 14
- 235000013305 food Nutrition 0.000 claims abstract description 13
- 235000008322 Trichosanthes cucumerina Nutrition 0.000 claims abstract description 12
- 150000001875 compounds Chemical class 0.000 claims abstract description 10
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 6
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims abstract description 4
- 229940107187 fructooligosaccharide Drugs 0.000 claims abstract description 4
- 244000302512 Momordica charantia Species 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 17
- 238000004108 freeze drying Methods 0.000 claims description 15
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 9
- 235000009812 Momordica cochinchinensis Nutrition 0.000 claims description 8
- 235000018365 Momordica dioica Nutrition 0.000 claims description 8
- 238000004140 cleaning Methods 0.000 claims description 8
- 238000000227 grinding Methods 0.000 claims description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- 238000005520 cutting process Methods 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 4
- 238000004537 pulping Methods 0.000 claims description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 3
- 229930003268 Vitamin C Natural products 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 235000019154 vitamin C Nutrition 0.000 claims description 3
- 239000011718 vitamin C Substances 0.000 claims description 3
- 241000894006 Bacteria Species 0.000 claims description 2
- 241000245665 Taraxacum Species 0.000 claims 3
- 239000002417 nutraceutical Substances 0.000 claims 1
- 235000021436 nutraceutical agent Nutrition 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 20
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 16
- 240000001949 Taraxacum officinale Species 0.000 abstract description 14
- 239000003814 drug Substances 0.000 abstract description 13
- 229940079593 drug Drugs 0.000 abstract description 6
- 231100000331 toxic Toxicity 0.000 abstract description 6
- 230000002588 toxic effect Effects 0.000 abstract description 6
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 239000004480 active ingredient Substances 0.000 abstract description 2
- 244000078912 Trichosanthes cucumerina Species 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 29
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 28
- 108010028144 alpha-Glucosidases Proteins 0.000 description 28
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 22
- 230000000052 comparative effect Effects 0.000 description 18
- 241000700159 Rattus Species 0.000 description 17
- 230000005764 inhibitory process Effects 0.000 description 17
- 235000018927 edible plant Nutrition 0.000 description 14
- 230000004083 survival effect Effects 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 239000003833 bile salt Substances 0.000 description 13
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
- 238000005259 measurement Methods 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 11
- 239000000725 suspension Substances 0.000 description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
- 239000008103 glucose Substances 0.000 description 9
- 230000001580 bacterial effect Effects 0.000 description 8
- 230000000529 probiotic effect Effects 0.000 description 8
- 235000020383 bitter gourd juice Nutrition 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 230000002195 synergetic effect Effects 0.000 description 7
- 239000012085 test solution Substances 0.000 description 7
- 102000004877 Insulin Human genes 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 229940125396 insulin Drugs 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 235000011305 Capsella bursa pastoris Nutrition 0.000 description 5
- 240000008867 Capsella bursa-pastoris Species 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 210000004051 gastric juice Anatomy 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 244000113428 Sonchus oleraceus Species 0.000 description 4
- 235000006745 Sonchus oleraceus Nutrition 0.000 description 4
- 235000010489 acacia gum Nutrition 0.000 description 4
- 239000003472 antidiabetic agent Substances 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 235000013402 health food Nutrition 0.000 description 4
- 230000003345 hyperglycaemic effect Effects 0.000 description 4
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000007865 diluting Methods 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 201000001421 hyperglycemia Diseases 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- -1 p-nitrophenol alpha-D-glucopyranoside Chemical class 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 239000003223 protective agent Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 210000004211 gastric acid Anatomy 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000009776 industrial production Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 2
- 229960003105 metformin Drugs 0.000 description 2
- 239000004570 mortar (masonry) Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 235000013406 prebiotics Nutrition 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 229960001052 streptozocin Drugs 0.000 description 2
- XPFJYKARVSSRHE-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].[Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O XPFJYKARVSSRHE-UHFFFAOYSA-K 0.000 description 2
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 229940122355 Insulin sensitizer Drugs 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 241000488874 Sonchus Species 0.000 description 1
- 235000008132 Sonchus arvensis ssp. uliginosus Nutrition 0.000 description 1
- 235000015360 Taraxacum officinale ssp. ceratophorum Nutrition 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 235000021070 high sugar diet Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 229940068140 lactobacillus bifidus Drugs 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000002352 surface water Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/173—Reuteri
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/515—Animalis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种降血糖组合物、制备方法及其应用,制成所述降血糖组合物的有效成分的原料包括物料A和物料B,以重量份数计,物料A包括苦瓜25~34份、苣荬菜8~13份、马齿苋25~34份和蒲公英15~24份;物料B包括桃胶粉0.08~0.12份、复配益生菌0.3~0.7份和低聚果糖0.3~0.7份;所述复配益生菌包括罗伊氏乳杆菌、乳双歧杆菌、鼠李糖乳杆菌、植物乳杆菌和副干酪乳杆菌;本发明提供的降血糖组合物无毒副作用,对糖尿病的预防、延缓和治疗具有积极意义;降血糖组合物的制备工艺合理、操作简单、原料来源广泛,利于工业化生产;降血糖组合物可广泛应用于制备食品、保健食品、膳食补充剂或药品。
Description
技术领域
本发明属于食品加工领域,涉及一种具有降血糖作用组合物的加工,具体地说是一种降血糖组合物、制备方法及其应用。
背景技术
随着人民生活方式的改变和生活水平的提高,因高糖饮食引发的糖尿病发病率呈逐步上升趋势,糖尿病日渐成为严重威胁人类健康的大敌。如果对糖尿病不加以治疗,持续的糖尿病还会导致如心脏病、心血管疾病、肾病等在内的多种并发症,据统计糖尿病已成为世界第八大死因。鉴于糖尿病的高患病率对社会经济发展具有重要影响,因此各国均在积极探索防治糖尿病的方案。
目前,糖尿病的预防、延缓和治疗,主要是通过生活方式干预(合理饮食、适量运动)和使用降糖药物治疗来进行的。其中,饮食控制是基础疗法,使用降糖药物是降低血糖(PG)、延缓和阻止糖尿病并发症的主要手段。降糖药物种类主要有α-糖苷酶抑制剂(如阿卡波糖)、胰岛素增敏剂(罗格列酮等)和双胍类(如二甲双胍等),但是临床常用降糖药物在控制病情的同时会带来诸如腹泻、腹胀等毒副作用,因此研究更安全的预防治疗糖尿病的方案显得尤为重要。
马齿苋、蒲公英、苦瓜、苣荬菜、苦苣菜等均为我国具有传统的药食同源植物;益生菌可升高Ⅱ型糖尿病患者的胰岛素敏感性、改善糖尿病患者的肠道菌群,从而利于血糖控制。因此,研究开发一款将药食同源植物与益生菌结合的具有降血糖作用且无副作用的组合物对于糖尿病的预防、延缓和治疗具有重要意义。
发明内容
本发明要解决的技术问题,是为潜在糖尿病患者及糖尿病患者提供一种安全、无毒副作用、可长期食用的降血糖组合物;
本发明的另一目的,旨在提供上述降血糖组合物的制备方法,制备方法简便、生产效率高,利于工业化生产;
本发明的另一目的,旨在提供上述降血糖组合物的应用,该组合物可广泛用于食品、保健食品、膳食补充剂或药品的制备。
为了实现上述目的,本发明采用的技术方案是:
一种降血糖组合物,制成它的有效成分的原料包括物料A和物料B,以重量份数计,
所述物料A包括苦瓜25~34份、苣荬菜8~13份、马齿苋25~34份和蒲公英15~24份;
所述物料B包括桃胶粉0.08~0.12份、复配益生菌0.3~0.7份和低聚果糖0.3~0.7份;
所述复配益生菌包括罗伊氏乳杆菌、乳双歧杆菌、鼠李糖乳杆菌、植物乳杆菌和副干酪乳杆菌。
作为对降血糖组合物的一种限定,所述降血糖组合物中益生菌活菌数为1.2×1010~2.8×1010CFU/g;
所述复配益生菌中罗伊氏乳杆菌、乳双歧杆菌、鼠李糖乳杆菌、植物乳杆菌和副干酪乳杆菌的活菌数比例为1:1~3:0.5~3:3~6:0.5~3。
作为对降血糖组合物的另一种限定,制成它的有效成分的原料,以重量份数计还包括柠檬酸0.1~0.25份和维生素C 0.05~0.15份。
本发明还提供了上述降血糖组合物的制备方法,该制备方法为:将苦瓜、苣荬菜、马齿苋和蒲公英破壁研磨后,加入物料A中的其他原料,冷冻干燥后与物料B混合均匀,进行二次冷冻干燥,即得所述降血糖组合物。
作为对上述制备方法的一种限定,所述破壁研磨前还包括预处理,所述预处理包括将苦瓜清洗、切块、打浆,将苣荬菜、马齿苋、蒲公英清洗、切段、粉碎、过滤。
作为对降血糖组合物制备方法的另一种限定,所述冷冻干燥温度为-30~-40℃、时间为24~36h。
作为对降血糖组合物制备方法的第三种限定,所述物料B中的桃胶粉配置为质量分数为8~12%的桃胶溶液后再与其他物料混合;
所述二次冷冻干燥温度为-30~-40℃、时间为24~36h。
本发明还提供了上述降血糖组合物的应用,所述的降血糖组合物用于制备食品、保健食品、膳食补充剂或药品。
由于采用了上述技术方案,本发明与现有技术相比,所取得的技术进步在于:
①本发明提供的降血糖组合物,精选组方,以药食同源植物、复配益生菌为主要原料,具有良好的降血糖作用且无毒副作用,糖尿病患者或潜在糖尿病患者可长期食用;
②本发明提供的降血糖组合物制备方法是根据选定的降血糖原料特性确定的,与选择常规干燥的植物原料进行粉碎相比,本发明选择将新鲜的药食同源植物原料经粉碎或打浆后进行冷冻干燥,其优势在于有效地保持新鲜物料的色、香、味,并最大限度保存物料中各种维生素、多肽、生物酶及氨基酸等生物活性成分及风味物质;
③本发明的选用的桃胶在本发明中兼具降血糖、冻干保护剂和益生元三重作用,特别是作为冻干保护剂的使用克服了益生菌货架期衰减快的技术障碍,为桃胶的综合利用提供理论依据和实践指导;
④本发明制备的降血糖组合物具有广泛的应用领域,可作为原料用于食品、保健食品、膳食补充剂或药品的制备。
综上所述,本发明提供的降血糖组合物无毒副作用,对糖尿病的预防、延缓和治疗具有积极意义;降血糖组合物的制备工艺合理、操作简单、原料来源广泛,利于工业化生产;降血糖组合物可广泛应用于制备食品、保健食品、膳食补充剂或药品。
附图说明
下面结合附图及具体实施例对本发明作更进一步详细说明。
图1为本发明实施例14中三种产品12个月内活菌数变化趋势图。
具体实施方式
下面通过具体实施例对本发明作进一步详细说明。应当理解所描述的实施例仅用于解释本发明,并不限定本发明。
本发明实施例中所使用的材料、试剂等,如无特殊说明,均可从商业途径得到;实施例中未注明具体条件的实验方法,通常按照常规条件,或按照制造厂家建议的条件。
实施例1具有降血糖作用的药食同源植物原料的筛选
本实施例通过相关资料查询及调研,通过预实验筛选出6种具有降血糖作用的药食同源植物,即为新鲜的苦瓜、苣荬菜、荠菜、苦苣菜、马齿苋、蒲公英;另外,《草药验方交流集》中记载桃胶可治疗糖尿病,因此将桃胶作为备选原料之一。
(1)原料的预处理
取新鲜的苣荬菜、荠菜、苦苣菜、马齿苋、蒲公英5种药食同源植物原料,清洗,沥干表面水分,采用研钵加入液氮充分进行研磨,分别得到五种破壁汁液;
取新鲜的苦瓜清洗、沥干表面水分,采用研钵加入液氮充分进行研磨,得到苦瓜汁液;
取桃胶粉(霆瑞牌,多糖含量为95%,山东霆瑞生物科技有限公司)10g加入至90g纯化水中,加热至桃胶粉完全溶解,制备成质量分数为10%的桃胶溶液,放凉备用。
(2)药食同源植物原料降血糖作用的体外研究
分别吸取本实施例步骤(1)制备的苦瓜汁液、苣荬菜汁液、荠菜汁液、苦苣菜汁液、马齿苋汁液、蒲公英汁液、桃胶溶液各200μL置于不同试管中,每支试管中加入20U/mL的α-葡萄糖苷酶溶液200μL,37℃保温10min;再加入20mmol/L的对硝基苯酚α-D-吡喃葡萄糖苷溶液(PNPG)200μL,37℃中继续反应20min;最后加入1moL/L的Na2CO31mL终止反应,96孔板点样,在405nm处测量其吸光值,计算公式如公式1所示。
式中ODA——加入了待测样品和α-葡萄糖苷酶的吸光值;ODB——加入了待测样品不含α-葡萄糖苷酶的吸光值;ODC——加入了α-葡萄糖苷酶但不含待测样品的吸光值;ODD——既不含待测样品也不含α-葡萄糖苷酶的吸光值。
按照上述方法测定七种药食同源植物原料的α-葡萄糖苷酶抑制活性,其测定结果如表1所示。
表1七种药食同源植物原料对α-葡萄糖苷酶抑制率测定结果
由表1结果可知:苦瓜、苣荬菜、马齿苋和蒲公英对α-葡萄糖苷酶的抑制率超过30%,选作本发明的原料;荠菜、苦苣菜对α-葡萄糖苷酶的抑制率偏低,分别为16.79%、11.92%,暂不选为本发明实验用原料;桃胶对α-葡萄糖苷酶抑制率超过20%,且其具有胶体活性,冷冻干燥时桃胶具有成为冻干保护剂的潜在可能,同时能作为益生元可促进肠道益生菌生长,选为本发明的原料。
(3)不同药食同源植物原料之间协同作用研究
另外,本实施例欲考察选定的不同药食同源植物原料之间在降血糖作用方向上是否具有协同作用,具体方法如下:
首先制备5组对比实施例,其中对比实施例1为选择本实施例步骤(1)制备的苦瓜汁液10mL,作为待测液1;对比实施例2为选择本实施例步骤(1)制备的苦瓜汁液、苣荬菜汁液各5mL,混合均匀,作为待测液2;对比实施例3为选择本实施例步骤(1)制备的苦瓜汁液、苣荬菜汁液、马齿苋汁液各3.33mL,混合均匀,作为待测液3;对比实施例4为选择本实施例步骤(1)制备的苦瓜汁液、苣荬菜汁液、马齿苋汁液、蒲公英汁液各2.5mL,混合均匀,作为待测液4;对比实施例5为选择本实施例步骤(1)制备的苦瓜汁液、苣荬菜汁液、马齿苋汁液、蒲公英汁液、质量分数为10%的桃胶溶液各2.0mL,混合均匀,作为待测液5。
按照本实施例步骤(2)所述的方法测定待测液1-5的α-葡萄糖苷酶抑制活性,测定结果如表2所示。
表2待测液1-5对α-葡萄糖苷酶抑制率测定结果
注:与待测液1相比,*表示在p=0.05水平下差异显著
由表2实验数据可知,随着不同药食同源植物原料的逐步增加,在降血糖方向不同药食同源植物原料之间出现协同作用,当苦瓜、苣荬菜、马齿苋、蒲公英同时使用时,其降血糖作用已高于单一苦瓜降血糖作用约8%;当桃胶添加到此混合物中,其降血糖作用显著高于单一苦瓜降血糖作用。
实施例2益生菌种类的选取
本实施例通过相关资料查询及调研,通过预实验筛选出5种具有降血糖作用的益生菌,分别为罗伊氏乳杆菌、乳双歧杆菌、鼠李糖乳杆菌、植物乳杆菌和副干酪乳杆菌,本实施例选择罗伊氏乳杆菌LL034、乳双歧杆菌BR018、鼠李糖乳杆菌GS043、植物乳杆菌LZ022和副干酪乳杆菌GF040作为本实验的实验菌株。其中,罗伊氏乳杆菌LL034(2×1011CFU/g)、乳双歧杆菌BR018(4×1011CFU/g)、鼠李糖乳杆菌GS043(3×1011CFU/g)、植物乳杆菌LZ022(6×1011CFU/g)和副干酪乳杆菌GF040(3×1011CFU/g)均购自天津小薇生物有限公司。
(1)益生菌的预处理
将罗伊氏乳杆菌LL034、乳双歧杆菌BR018、鼠李糖乳杆菌GS043、植物乳杆菌LZ022和副干酪乳杆菌GF040,分别采用无菌生理盐水稀释到活菌数为1.2×1010CFU/g左右,备用。
(2)益生菌降血糖作用的体外研究
分别吸取本实施例步骤(1)制备的五种菌悬液200μL置于不同试管中,每支试管中加入20U/mL的α-葡萄糖苷酶溶液200μL,37℃保温10min;再加入20mmol/L的对硝基苯酚α-D-吡喃葡萄糖苷溶液(PNPG)200μL,37℃中继续反应20min;最后加入1moL/L的Na2CO31mL终止反应,96孔板点样,在405nm处测量其吸光值,计算公式如实施例1中公式1所示。
按照上述方法测定五种益生菌的α-葡萄糖苷酶抑制活性,其测定结果如表3所示。
表3五种益生菌对α-葡萄糖苷酶抑制率测定结果
由表3结果可知:乳双歧杆菌BR013、鼠李糖乳杆菌GS043、罗伊氏乳杆菌LL034、植物乳杆菌LZ022、副干酪乳杆菌GF040对α-葡萄糖苷酶均有抑制作用,其中罗伊氏乳杆菌LL034对α-葡萄糖苷酶的抑制率最高,为43.98%;乳双歧杆菌BR018、鼠李糖乳杆菌GS043、植物乳杆菌LZ022、副干酪乳杆菌GF040四菌株对α-葡萄糖苷酶抑制率均超过35%。因此,选择乳双歧杆菌BR018、鼠李糖乳杆菌GS043、罗伊氏乳杆菌LL034、植物乳杆菌LZ022和副干酪乳杆菌GF0405此五种益生菌作为本专利的益生菌原料。
(3)不同种类益生菌之间协同作用研究
另外,本实施例欲考察选定的不同种类益生菌之间在降血糖作用中是否具有协同作用,具体方法如下:
首先制备5组对比实施例,其中对比实施例6为选择本实施例步骤(1)制备的罗伊氏乳杆菌LL034菌悬液10mL,作为待测液6;对比实施例7为选择本实施例步骤(1)制备的罗伊氏乳杆菌LL034菌悬液、乳双歧杆菌BR018菌悬液各5mL,混合均匀,作为待测液7;对比实施例8为选择本实施例步骤(1)制备的罗伊氏乳杆菌LL034菌悬液、乳双歧杆菌BR018菌悬液、鼠李糖乳杆菌GS043菌悬液各3.33mL,混合均匀,作为待测液8;对比实施例9为选择本实施例步骤(1)制备的罗伊氏乳杆菌LL034菌悬液、乳双歧杆菌BR018菌悬液、鼠李糖乳杆菌GS043菌悬液、植物乳杆菌LZ022各2.5mL,混合均匀,作为待测液9;对比实施例10为选择本实施例步骤(1)制备的罗伊氏乳杆菌LL034菌悬液、乳双歧杆菌BR018菌悬液、鼠李糖乳杆菌GS043菌悬液、植物乳杆菌LL022、副干酪乳杆菌GF040菌悬液各2.0mL,混合均匀,作为待测液10。
按照本实施例步骤(2)所述的方法测定待测液6-10的α-葡萄糖苷酶抑制活性,测定结果如表4所示。
表4待测液6-10对α-葡萄糖苷酶抑制率测定结果
注:与待测液6相比,*表示在p=0.05水平下差异显著
由表4实验数据可知,随着五种不同益生菌种类的逐步增加,相应待测液对α-葡萄糖苷酶抑制作用逐步增加,说明不同菌株之间出现协同作用。当五种益生菌同时使用,相对于罗伊氏乳杆菌LL034的单一菌株,对α-葡萄糖苷酶抑制率出现显著差异性。
实施例3一种降血糖组合物的制备方法
本实施例为降血糖组合物的制备方法,具体包括依次进行的以下步骤:
S1.将30kg新鲜的苦瓜清洗、切块、打浆,得苦瓜汁液;
分别取10kg新鲜的苣荬菜、30kg新鲜的马齿苋、20kg新鲜的蒲公英,清洗、切段、粉碎,过100目筛,得混合汁液1;
将苦瓜汁液与混合汁液1混合均匀,得物料A0;
S2.将0.12kg柠檬酸与0.08kg维生素C添加至物料A0中,混合均匀,采用胶体磨破壁研磨,制得物料A1;
S3.物料A1在60℃、真空度为0.08MPa条件下真空浓缩至ρ为1.05~1.50g/L的浓缩液,浓缩液在-30℃条件下冷冻干燥34h,制得冻干粉A 8.83kg;
S4.取桃胶粉(霆瑞牌,多糖含量为95%,山东霆瑞生物科技有限公司)0.1kg加入至0.9kg纯化水中,加热至桃胶粉完全溶解,制备成1kg质量分数为10%的桃胶溶液,放凉备用;
按质量比为1:1:1:2:0.5称取罗伊氏乳杆菌LL034、乳双歧杆菌BR018、鼠李糖乳杆菌GS043、植物乳杆菌LL022和副干酪乳杆菌GF040菌粉,制成复配益生菌粉,此时复配益生菌粉中罗伊氏乳杆菌LL034、乳双歧杆菌BR018、鼠李糖乳杆菌GS043、植物乳杆菌LL022和副干酪乳杆菌GF040中活菌数比为1:2:1.5:3:0.75;
将复配益生菌粉500g、低聚果糖500g、质量分数为10%桃胶溶液1kg混合均匀,制得物料B;
将步骤S3制备的冻干粉A 8.83kg与物料B,充分混匀,过30目筛,进行造粒;将造粒后的物料在-30℃条件下冷冻干燥34h,制得样品C 9.72kg,样品C即为所述降血糖组合物。
实施例4~9降血糖组合物的制备方法
实施例4~9分别为一种降血糖组合物的制备方法,它们的步骤与实施例3基本相同,不同之处仅在于各项参数不同,具体详见表5。
表5实施例4~9中各项参数一览表
实施例11降血糖组合物耐酸耐胆盐特性实验
本实施例分降血糖组合物对开展了耐酸性实验和耐胆盐实验,包含以下内容:
(1)耐酸性实验
S1.人工胃液的制备
取10%的盐酸加去离子水稀释,分别调节pH为2.0、3.0,加入胃蛋白酶使其终浓度为1%,再用盐酸调整溶液的pH为2.0、3.0。在无菌操作台中,用0.22μm的微孔滤膜过滤后备用;
S2.耐酸性实验
取0.5g样品C,与4.5mL的不同pH值的人工胃液混合,于37℃培养箱中静置培养分别于2h、4h后取样,稀释涂布平板后37℃培养24h,测定菌落数。以未经人工胃液处理的菌落数作为对照,计算存活率,降血糖组合物耐酸实验结果见下表表6。
表6降血糖组合物耐酸性实验结果
注:未经人工胃液处理的菌落数对2.2×109CFU/mL。
由表4实验结果可看出,样品C在人工胃液pH=2,培养2h时存活率超过10%;在人工胃液pH=3时能大量存活,培养2h存活率大于80%,培养4h存活率大于75%;因此该降血糖组合物具有很好的耐胃酸特性,在饭后食用该降血糖组合物,样品中的益生菌能很好地通过胃酸环境到达肠道。
(2)耐胆盐实验
S1.胆盐溶液的制备
配制含胆盐浓度为0.3%的MRS培养基;
S2.耐胆盐实验研究
按2%比例将样品C接入50mL胆盐浓度为0.3%的胆MRS培养基中,37℃培养2h、4h。取样,梯度稀释,涂布MRS平板,37℃培养24h,测定菌落数。以未经胆盐溶液处理的菌落数作为对照,计算存活率,降血糖组合物耐胆盐实验结果见下表表7。
表7降血糖组合物耐胆盐实验结果
培养时间(h) | 胆盐浓度(%) | 活菌数(CFU/mL) | 存活率(%) |
2 | 0.3 | 3.60×10<sup>8</sup> | 81.82±3.07 |
4 | 0.3 | 3.85×10<sup>8</sup> | 87.50±3.41 |
注:未经胆盐溶液处理的菌落数对4.4×108CFU/mL。
由表7实验结果可知,样品C在0.3%胆盐浓度的培养基中存活率大于80%,随着时间延长,益生菌活菌数略有增长,说明降血糖组合物中的益生菌在肠道中能大量存活,进而发挥作用。
实施例12降血糖组合物降血糖作用的体外研究
分别取本实施例3~9制备的降血糖组合物0.4g,置于不同试管中,每支试管中加入20U/mL的α-葡萄糖苷酶溶液400μL,37℃保温10min;再加入20mmol/L对硝基苯酚α-D-吡喃葡萄糖苷溶液(PNPG)400μL,37℃中继续反应20min;最后加入1moL/L的Na2CO31mL终止反应,96孔板点样,在405nm处测量其吸光值,计算公式如实施例1中公式1所示。
按照上述方法测定α-葡萄糖苷酶抑制活性,其测定结果下表表8所示。
表8降血糖组合物对α-葡萄糖苷酶抑制率测定结果
由表8实验数据可知,实施例3~9制备的降血糖组合物对α-葡萄糖苷酶抑制率均超过90%。然而,药食同源植物原料单独或复合使用、益生菌单独或复合使用时对α-葡萄糖苷酶的抑制率在50%左右,因此发现药食同源植物原料与益生菌组合可大大提高对α-葡萄糖苷酶的抑制率,其原因可能在于药食同源植物原料与益生菌复合使用可产生协同效应,进一步发挥更显著的降糖作用。
实施例13降血糖组合物对高血糖大鼠的影响
本实施例考察降血糖组合物对链脲佐菌素STZ诱导的高血糖大鼠的影响,具体方法如下:
首先制备一组对比实施例,即对比实施例7,对比实施例7为在实施例3的配方基础上,仅不添加益生菌粉,其余原料的种类、数量及制备工艺不做变动,制得的产品记为样品D;
选取体重180±20g的健康雄性Wistar大鼠50只,环境适应性饲养一周。将按体重随机将大鼠分为空白对照组、模型组、样品D组、样品C组、阳性对照组,每组10只,所有大鼠单笼饲养。其中,空白对照组在正常环境下正常饲养;模型组、阳性对照组、样品D组、样品C组,喂食高脂饲料,8周后,腹腔注射链脲佐菌素STZ(用灭菌的0.1mol·L-1,pH4.4的柠檬酸-柠檬酸钠缓冲液配置成2%的溶液,现用现配)35mg·kg-1进行造模,空白对照组腹腔注射等量的柠檬酸-柠檬酸钠缓冲液。注射STZ一周后取血,用血糖仪测定血糖值,以血糖值≥16.7·L-1作为造模成功,模型制备成功后各组喂食普通饲料。
造模成功后将空白对照组和模型组大鼠在正常环境下正常饲养;阳性对照组大鼠按照用药剂量为200mg/kg 1次/d灌胃给药7周;样品D组大鼠按照用药剂量为0.1g/kg,1次灌胃给药7周;样品C组大鼠按照用药剂量为0.1g/kg,1次/d灌胃给药7周。
大鼠空腹血糖(FBG)指标测定:测定给药第0周、第1周、第2周、第3周、第4周、第5周、第6周、第7周小鼠空腹血糖值,测空腹血糖当天禁食2h,剪尾取全血10μL,用血糖仪测定并记录大鼠空腹血糖值,测定结果见表8。
表8不同组别大鼠空腹血糖值测定结果
注:与模型组相比较:*P<0.05,**P<0.01。
由表8实验数据可知,通过7周给药实验,阳性对照组能逐步稳定降低血糖含量,在给药第2周时与模型组出现显著性差异性(P<0.05),在给药第6周时与模型组具有极显著差异性(P<0.01);样品D组在给药第4周-给药第7周与模型组具有显著性差异(P<0.05);样品C组与样品D组给药前两周降血糖效果基本相同,但给药第3周时,样品C组降血糖效果明显优于样品D组,与模型组相比具显著性差异性(P<0.05),给药第6周时与模型组相比差异极显著(P<0.01)。样品C较样品D有显著的降血糖作用,虽与药品二甲双胍相比降血糖作用略低,但本降血糖组合物由食品原料或药食同源原料经精心组方而成,即使长期食用也无毒副作用,安全系数高。
第7周给药2h后,取各组大鼠眼静脉血,测定血清胰岛素含量,测定结果见表9。
表9给药第7周不同组别大鼠血清胰岛素含量测定结果
注:与模型组相比较:*P<0.05,**P<0.01。
由表9实验数据可知:模型组大鼠血清胰岛素水平较空白对照组显著降低,给予样品D和降血糖组合物7周后大鼠血清胰岛素水平明显回升,样品D组较样品C组血清胰岛素低,样品C组较阳性对照组的血清胰岛素水平略低。
实施例14不同种类的胶对组合物货架期内益生菌存活率的影响
本实施例的目的在于考察桃胶、阿拉伯胶和明胶三种不同种类的胶对组合物货架期内益生菌存活率的影响,具体方法如下:
首先制备2组对比实施例,其中对比实施例11为在实施例3的基础上,将S4中的桃胶粉0.1kg更换为阿拉伯胶(鼎力牌,多糖含量为80%,泰安市鼎力胶业有限公司)0.1kg,其余原料的种类、数量及制备工艺不做变动,制得样品E;对比实施例12为在实施例3的基础上,将S4中的桃胶粉0.1kg更换为明胶(罗赛洛牌,罗赛洛(温州)明胶有限公司)0.1kg,其余原料的种类、数量及制备工艺不做变动,制得样品F。
在温度为25~30℃、相对湿度35~40%下,对样品C、样品E和样品F进行为期12个月内产品活菌数进行计数跟踪,其结果如表10所示;三种产品12个月内活菌数变化趋势图如图1所示。
表10不同产品活菌数计数跟踪表
时间 | 样品C | 样品E | 样品F |
0 | 1.73×10<sup>10</sup> | 1.69×10<sup>10</sup> | 1.74×10<sup>10</sup> |
1月 | 1.71×10<sup>10</sup> | 1.65×10<sup>10</sup> | 1.7×10<sup>10</sup> |
2月 | 1.68×10<sup>10</sup> | 1.53×10<sup>10</sup> | 1.64×10<sup>10</sup> |
3月 | 1.62×10<sup>10</sup> | 1.46×10<sup>10</sup> | 1.57×10<sup>10</sup> |
4月 | 1.56×10<sup>10</sup> | 1.32×10<sup>10</sup> | 1.48×10<sup>10</sup> |
5月 | 1.48×10<sup>10</sup> | 1.19×10<sup>10</sup> | 1.35×10<sup>10</sup> |
6月 | 1.41×10<sup>10</sup> | 1.06×10<sup>10</sup> | 1.24×10<sup>10</sup> |
7月 | 1.34×10<sup>10</sup> | 0.94×10<sup>10</sup> | 1.16×10<sup>10</sup> |
8月 | 1.22×10<sup>10</sup> | 0.85×10<sup>10</sup> | 1.03×10<sup>10</sup> |
9月 | 1.15×10<sup>10</sup> | 0.73×10<sup>10</sup> | 0.91×10<sup>10</sup> |
10月 | 1.01×10<sup>10</sup> | 0.67×10<sup>10</sup> | 0.84×10<sup>10</sup> |
11月 | 0.93×10<sup>10</sup> | 0.59×10<sup>10</sup> | 0.73×10<sup>10</sup> |
12月 | 0.84×10<sup>10</sup> | 0.52×10<sup>10</sup> | 0.61×10<sup>10</sup> |
由表10实验结果和图1可知,样品C、样品E和样品F在25~30℃、相对湿度35~40%条件下存放12个月,益生菌存活率成下降趋势,其中样品C存活率为48.56%,样品E存活率为30.77%,样品F存活率为35.06%;三种产物仅存在桃胶、阿拉伯胶和明胶的区别,说明三种含益生菌产品在常温保存过程中,对益生菌有有益影响的原料顺序为:桃胶>明胶>阿拉伯胶,桃胶的作用明显有利于益生菌存活率。
实施例14人群试服实验
本实施例的目的在于考察降血糖组合物对高血糖人群血糖的影响,具体方法如下:
(1)受试人群的选定标准
Ⅱ型糖尿病人群:选择经饮食控制或口服降糖药物治疗后病情较稳定、仅服用维持量的成年Ⅱ型糖尿病人,不需要更换药物品种及剂量,空腹血糖≧7.8mmol/L或餐后2h血糖≧11.1mmol/L;
高血糖人群:选择7.8mmol/L≧空腹血糖≧6.7mmol/L或11.1mmol/L≧餐后2h血糖≧7.8mmol/L的高血糖人群。
(2)试服实验
Ⅱ型糖尿病人群及高血糖人群各选择30名,随机分成两组,每组Ⅱ型糖尿病人和高血糖人群各15名,分别试用样品D和降血糖组合物,期间服用药物和饮食不做改变。
样品D和降血糖组合物食用量为5g/次,每日早晚两次,餐后食用,食用周期为1个月,测定记录使用样品前以及使用样品1个月后每组人群空腹血糖值,并计算数据,其结果表10所示。
表10试服实验结果
由表10数据可知,所有试服人群服用样品D和降血糖组合物一个月后,所分组内试服人群血糖平均值都降低,其中样品D组血糖平均值较样品C组血糖平均值下降较少,说明降血糖组合物比样品D作用显著;试服有效率样品C组比样品D组明显;样品D和降血糖组合物对高血糖人群作用显著,有效率高,但对Ⅱ型糖尿病人群作用显著性和有效率略低。
Claims (8)
1.一种降血糖组合物,其特征在于,制成它的有效成分的原料包括物料A和物料B,以重量份数计,
所述物料A包括苦瓜25~34份、苣荬菜8~13份、马齿苋25~34份和蒲公英15~24份;
所述物料B包括桃胶粉0.08~0.12份、复配益生菌0.3~0.7份和低聚果糖0.3~0.7份;
所述复配益生菌包括罗伊氏乳杆菌、乳双歧杆菌、鼠李糖乳杆菌、植物乳杆菌和副干酪乳杆菌。
2.根据权利要求1所述的一种降血糖组合物,其特征在于,所述降血糖组合物中复配益生菌的活菌数为1.2×1010~2.8×1010CFU/g;
所述复配益生菌中罗伊氏乳杆菌、乳双歧杆菌、鼠李糖乳杆菌、植物乳杆菌和副干酪乳杆菌的活菌数比例为1:1~3:0.5~3:3~6:0.5~3。
3.根据权利要求1或2所述的一种降血糖组合物,其特征在于,所述物料A,以重量份数计还包括柠檬酸0.1~0.25份和维生素C 0.05~0.15份。
4.根据权利要求1~3中任一项所述的降血糖组合物的制备方法,其特征在于,所述制备方法为:将苦瓜、苣荬菜、马齿苋和蒲公英破壁研磨后,加入物料A中的其他原料,冷冻干燥后与物料B混合均匀,进行二次冷冻干燥,即得所述降血糖组合物。
5.根据权利要求4所述的降血糖组合物的制备方法,其特征在于,所述破壁研磨前还包括预处理,所述预处理包括将苦瓜清洗、切块、打浆,将苣荬菜、马齿苋、蒲公英清洗、切段、粉碎、过滤。
6.根据权利要求4所述的降血糖组合物的制备方法,其特征在于,所述冷冻干燥温度为-30~-40℃、时间为24~36h。
7.根据权利要求4所述的降血糖组合物的制备方法,其特征在于,所述物料B中的桃胶粉配置为质量分数为8~12%的桃胶溶液后再与其他物料混合;
所述二次冷冻干燥温度为-30~-40℃、时间为24~36h。
8.根据权利要求1~3中任一项所述的降血糖组合物的应用,其特征在于,所述的降血糖组合物用于制备食品、保健食品、膳食补充剂或药品。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211143554.8A CN115463176A (zh) | 2022-09-20 | 2022-09-20 | 一种降血糖组合物、制备方法及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211143554.8A CN115463176A (zh) | 2022-09-20 | 2022-09-20 | 一种降血糖组合物、制备方法及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115463176A true CN115463176A (zh) | 2022-12-13 |
Family
ID=84333549
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211143554.8A Pending CN115463176A (zh) | 2022-09-20 | 2022-09-20 | 一种降血糖组合物、制备方法及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115463176A (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106174585A (zh) * | 2016-06-30 | 2016-12-07 | 山东凤凰生物有限公司 | 降血糖的组合物及降血糖的复合益生菌特膳食品 |
CN110496183A (zh) * | 2019-09-30 | 2019-11-26 | 仲建福 | 一种用于治疗糖尿病的浓缩片及其制备方法 |
CN112089054A (zh) * | 2020-09-22 | 2020-12-18 | 上海泓商生物科技有限公司 | 降血糖益生菌组合物 |
-
2022
- 2022-09-20 CN CN202211143554.8A patent/CN115463176A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106174585A (zh) * | 2016-06-30 | 2016-12-07 | 山东凤凰生物有限公司 | 降血糖的组合物及降血糖的复合益生菌特膳食品 |
CN110496183A (zh) * | 2019-09-30 | 2019-11-26 | 仲建福 | 一种用于治疗糖尿病的浓缩片及其制备方法 |
CN112089054A (zh) * | 2020-09-22 | 2020-12-18 | 上海泓商生物科技有限公司 | 降血糖益生菌组合物 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105146614B (zh) | 一种功能性钙果酵素、酵素饮料及其生产方法 | |
US6953574B2 (en) | Method for producing a fermented hydrolyzed medium containing microorganisms | |
EP2647694B1 (en) | Dead lactobacillus biomass for antimicrobial use and a production method therefor | |
EP1885207B1 (en) | Compositions for enteral application of microorganisms | |
CN109666615A (zh) | 一种益生菌组合物及其应用 | |
CN104982928B (zh) | 一种红豆杉果保健酵素及其制备方法 | |
CN109628358A (zh) | 一种复合益生菌及其应用 | |
EP2271367B1 (en) | Mineral absorption accelerator and iron deficiency anemia improver or food composition | |
CN114574406B (zh) | 鼠李糖乳杆菌菌株wka55及其在制备防治酒精性肝损伤制品方面的用途与产品 | |
US20050281898A1 (en) | Anti-tumor agent, beverages and foods using the same, and a process for manufacturing the anti-tumor agent | |
CN106858577A (zh) | 制备具有保肝护肝、调节脂肪肝代谢功能的植物酵素的发酵组合物及制法 | |
CN110522034A (zh) | 一种含有黑大麦乳杆菌发酵物的功能性食品及应用 | |
KR100943747B1 (ko) | 락토바실러스 가세리 bnr17 균주를 포함하는 당뇨병예방 및 치료용 조성물 | |
CN103750102B (zh) | 具有降糖功效的含有黑莓的组合物及其制备方法 | |
KR102483912B1 (ko) | 연질캡슐형 건강기능식품의 제조방법 | |
JP6301024B2 (ja) | フィーカリバクテリウム属細菌増殖剤 | |
JP2003252770A (ja) | 糖尿病合併症予防・改善・治療剤 | |
CN114621896B (zh) | 一株具有降糖降脂功能的植物乳杆菌84-3及其应用 | |
CN115463176A (zh) | 一种降血糖组合物、制备方法及其应用 | |
CN115363155A (zh) | 一种具有缓解体力疲劳的益生菌发酵莲子组合物的制备 | |
CN113854549A (zh) | 一种复合果蔬发酵组合物及其制备方法 | |
CA3137104A1 (en) | Microbial compositions and methods for greater tolerability and prolonged shelf life | |
Kumaraguruparaswami et al. | Spirulina-derived nutraceuticals and their applications in the food industry | |
WO2023000408A1 (zh) | 包含β-烟酰胺单核苷酸和刺梨提取物的组合物及其应用 | |
KR102581570B1 (ko) | 신규 바실러스 벨레젠시스 균주를 포함하는 면역증강용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |